Product Description
Bone morphogenetic protein-2 (BMP-2) is currently the only Food and Drug Administration (FDA)-approved osteoinductive growth factor used as a bone graft substitute. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964756/)
Mechanisms of Action: Bone formation Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Percutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other
Phase 2: Periodontitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| novel biomarkers and ISR | N/A |
Not yet recruiting |
Coronary Restenosis |
2025-01-01 |
|
| JapicCTI-205101 | P2 |
Unknown |
Unknown |
2022-05-31 |
|
| ChiCTR2100047693 | N/A |
Completed |
Osteoporosis|Transplantation Unspecified|Neuromyelitis Optica|Lyme Disease|Surgical Wound Infection |
2021-06-16 |
|
| NF107-BMP2 | N/A |
Terminated |
Pseudarthrosis|Neurofibromatosis 1|Neurofibromatoses |
2020-06-01 |